-
公开(公告)号：US20170285013A1
公开(公告)日：2017-10-05
申请号：US15591531
申请日：2017-05-10
IPC分类号： G01N33/50 , G01N33/68 , C07K16/40 , A61K38/48 , A61K38/19 , G01N33/569 , A61K31/727 , A61K31/56 , A61K31/352 , A61K35/19
CPC分类号： G01N33/5094 , A61K31/352 , A61K31/56 , A61K31/727 , A61K35/19 , A61K38/196 , A61K38/4886 , C07K16/40 , G01N33/56972 , G01N33/6893 , G01N2800/226
摘要： The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.
-
公开(公告)号：US20150079613A1
公开(公告)日：2015-03-19
申请号：US14453268
申请日：2014-08-06
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N33/6863 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
摘要翻译： 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。
-
公开(公告)号：US20210285964A1
公开(公告)日：2021-09-16
申请号：US17161783
申请日：2021-01-29
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
-
公开(公告)号：US20200306349A1
公开(公告)日：2020-10-01
申请号：US16309047
申请日：2017-06-15
发明人： Yan YAN , Anumeha SHAH , Ashmita SAIGAL , Herman GRIFFIN , Susan Faas MCKNIGHT , Andre MAROZSAN , Kim ASKEW , Yvonne NITSCHKE , Frank RUTSCH
IPC分类号： A61K38/46 , A01K67/027
摘要： The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
-
公开(公告)号：US20160033514A1
公开(公告)日：2016-02-04
申请号：US14827693
申请日：2015-08-17
发明人： Susan Faas MCKNIGHT , Roxanne COFIELL , Yan YAN
IPC分类号： G01N33/574 , G01N33/50
CPC分类号： G01N33/57492 , A61K39/39558 , A61K2039/505 , A61K2039/545 , A61K2039/57 , C07K16/2803 , G01N33/5091 , G01N33/5094 , G01N33/57484 , G01N33/68 , G01N2333/70517 , G01N2333/70596 , G01N2800/52
摘要： The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient.
-
6.发明申请公开(公告)号：US20200172603A1
公开(公告)日：2020-06-04
申请号：US16614582
申请日：2018-05-21
发明人： Orly Eshach ADIV , Camille BEDROSIAN , Hagit Baris FELDMAN , Alina KUROLAP , Susan Faas MCKNIGHT
摘要： Provided are methods for clinical treatment of a protein-losing enteropathy, such as lymphangiectasia, using an anti-C5 antibody, or antigen binding fragment thereof, in patients (e.g., pediatric patients).
-
公开(公告)号：US20170023590A1
公开(公告)日：2017-01-26
申请号：US15287162
申请日：2016-10-06
CPC分类号： G01N33/6893 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N33/6863 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
摘要翻译： 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。
-
公开(公告)号：US20160154009A1
公开(公告)日：2016-06-02
申请号：US15013833
申请日：2016-02-02
CPC分类号： G01N33/6893 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N33/6863 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
摘要翻译： 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.02 秒)
